Compare
enVVeno Medical Corp vs KORU Medical Systems, Inc. vs Interpace Biosciences, Inc. vs Vivos Therapeutics, Inc.
| Latest fiscal year | enVVeno Medical Corp NVNO | KORU Medical Systems, Inc. KRMD | Interpace Biosciences, Inc. IDXG | Vivos Therapeutics, Inc. VVOS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $41.13M | $38.73M | $17.44M |
| Revenue growth (YoY) | n/a | +22.2% | -17.5% | +16.0% |
| Gross margin | n/a | 62.3% | 62.3% | 60.4% |
| Operating margin | n/a | -7.2% | 10.5% | -114.1% |
| Net margin | n/a | -6.4% | 63.5% | -121.4% |
| Net income | -$19.47M | -$2.64M | $24.57M | -$21.17M |
| EPS (Diluted) | -$33.06 | -$0.06 | $0.89 | -$2.07 |
| Operating cash flow | -$15.57M | $462.4K | $5.83M | -$15.26M |
| Free cash flow | -$15.57M | -$470.1K | $5.47M | -$17.60M |
| Cash & equivalents | $3.06M | $8.87M | $2.50M | $2.03M |
| Total assets | $29.56M | $28.20M | $33.84M | $25.15M |
| Total liabilities | $2.43M | $11.15M | $11.47M | $26.70M |
| Shareholders' equity | $27.13M | $17.05M | $22.36M | -$1.49M |
| Return on year-end equity | -71.8% | -15.5% | 109.9% | n/a |
| Shares outstanding | 656.0K | 46.37M | 4.43M | 9.29M |
Revenue, most recent five fiscal years
| Fiscal year | enVVeno Medical Corp | KORU Medical Systems, Inc. | Interpace Biosciences, Inc. | Vivos Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $31.2K Ended 2019-12-31 | $41.13M Ended 2025-12-31 | $38.73M Ended 2025-12-31 | $17.44M Ended 2025-12-31 |
| 1 year earlier | $186.6K Ended 2018-12-31 | $33.65M Ended 2024-12-31 | $46.93M Ended 2024-12-31 | $15.03M Ended 2024-12-31 |
| 2 years earlier | $422.1K Ended 2017-12-31 | $28.52M Ended 2023-12-31 | $40.04M Ended 2023-12-31 | $13.80M Ended 2023-12-31 |
| 3 years earlier | n/a | $27.90M Ended 2022-12-31 | $31.84M Ended 2022-12-31 | $16.02M Ended 2022-12-31 |
| 4 years earlier | n/a | $23.49M Ended 2021-12-31 | $33.12M Ended 2021-12-31 | $16.89M Ended 2021-12-31 |